Pharmacovigilance in the era of real-world data
A medicine’s licence is the beginning of its safety story, not the end. Modern pharmacovigilance is one of the fastest-evolving disciplines in the life sciences.
No clinical trial can fully characterise a medicine’s safety. Pre-approval studies involve limited numbers of patients, follow them for limited periods, and often exclude the elderly, the pregnant, the multi-morbid and the very young — precisely the people who will take the medicine once it is marketed. Rare adverse reactions, delayed effects and interactions in complex patients can only be detected once a product is used at scale in real populations. That is the permanent case for pharmacovigilance.
From thalidomide to modern systems
Modern drug-safety science was born from failure: the thalidomide disaster of the late 1950s and early 1960s, in which a sedative marketed to pregnant women caused severe congenital malformations in thousands of children, led directly to the systematic adverse-event reporting and stronger licensing requirements that define regulation today.[1] Six decades later, pharmacovigilance is a globally harmonised discipline: national and regional systems collect spontaneous reports at scale, and international standards — from the ICH guidelines to the EU’s Good Pharmacovigilance Practices modules — define how marketing-authorisation holders must detect, assess and act on safety signals across a product’s entire lifecycle.
What is changing now
- Signal detection at scale. Large spontaneous-reporting databases are mined with disproportionality statistics and, increasingly, machine-learning methods across the pharmacovigilance lifecycle[2] — demanding analysts who understand both the pharmacology and the limitations of the data.
- Real-world evidence. Electronic health records, claims data and registries now complement spontaneous reports — the US FDA finalised dedicated guidance on using EHR and claims data for regulatory decision-making in 2024[3] — supporting faster hypothesis testing and formal post-authorisation safety studies.
- Lifecycle obligations. Risk-management plans, periodic safety-update reports and post-market surveillance duties for medical devices have turned safety from a reactive function into a continuous, planned discipline.
The career signal: pharmacovigilance, post-market surveillance and real-world-evidence roles consistently appear among the most in-demand functions in pharmaceutical and medical-device organisations — and they increasingly require demonstrable, assessed competence rather than on-the-job familiarity alone.
Professional recognition in drug safety
The EUSTM Academy addresses this space with three complementary credentials: the Professional Certification in Drug Safety & Pharmacovigilance (PCDSPV) for the core discipline, the Professional Certification in Real-World Evidence (PCRWE) for observational data science, and the Professional Certification in Post-Market Surveillance (PCPMS) for device vigilance.
References
- Javid M, Nandave M, Kumar A. History of Pharmacovigilance. In: Pharmacovigilance Essentials. Springer, Singapore (2024). doi: 10.1007/978-981-99-8949-2_2
- An industry perspective on the use of machine learning in drug and vaccine safety. Frontiers in Drug Safety and Regulation (2023). doi: 10.3389/fdsfr.2023.1110498
- US Food and Drug Administration. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products — final guidance (2024). fda.gov
Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.
← All Expert Insights